ClinicalTrials.gg
Active, not recruitingNCT04145882Updated Feb 29, 2024

Efficacy of Additional Osteotomies to Correct Hallux Valgus

An interventional study of additional osteotomies in Hallux Valgus, sponsored by Elsan. Active, not recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Elsan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 17 studies in Hallux Valgus with a site in France — 3 open to participants now, 5 under way, none of them phase 3. Hallux Valgus · France.

Enrollment
Largest of 13
515 · median 74
Started
2019
with 2 others
No phase
13 of 17
3 open now
Registered
7th of 17
by date
Lead sponsor
1 of 17
Elsan

Among the 17 studies in Hallux Valgus with a site in France, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 with no phase, and was the 7th registered.

Hallux Valgus

157 studies on the registry are indexed under Hallux Valgus; 36 are open to participants now.

Browse Hallux Valgus studies →

Open to participants now

3 of the 17 studies in Hallux Valgus with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 21 Hallux Valgus studies recruiting now, 10 (48%) set no upper age limit and 7 (33%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hallux Valgus with a site in France, or all of them as a file.
02

Study summary

Deviation of the big toe in valgus at the level of the first metatarsophalangeal joint is called Hallux Valgus. In case of significant pain especially due to a conflict with the shoes, surgery could be indicated. Angle between the first metatarsal (M1) and the first phalangeal (P1) is named Hallux Valgus Angle (HVA). Angle between M1 and the second metatarsal (M2) is named InterMetatarsal Angle (IMA). Angle between M1 distal articular surface and M1 shaft axis in a frontal plane is named Distal Metatarsal Articular Angle (DMAA).

Insufficient surgical correction is a risk factor of recurrence (HVA>20° after surgery). According to Okuda et al in a 67 patients group treated by proximal osteotomies correction, postoperative risk factors of recurrence at 33 month of follow-up are : HVA>40° before the surgery and HVA>15° with an IMA>10° 10 weeks (3-24) after the surgery.

Currently, one of the most common used procedure is a translated (laterally) distal chevron associated with a release of the metatarso-sesamoid suspensory ligament and a Akin procedure on P1. Nevertheless this procedure does not correct deformation in all plans. HVA and IMA are corrected but DMAA and M1 pronation angle are not.

Surgeons can add three different osteotomies in this type of chevron. In the dorsal saw cut a varisation wedge osteotomy is possible , in the plantar saw cut a supination wedge osteotomy is possible, and both are possible. No studies have tried to assess these three possibilities.

The investigators hypothesize that the addition of a varisation and/or a supination wedge osteotomies in a distal chevron decrease risk factors of recurrence at six months of follow-up

03

Conditions studied

  • Hallux Valgus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient older than 18 years.

Exclusion criteria

Exclusion Criteria:

  • Associated lesser metatarsals surgery.
  • Associated surgery on midfoot, hindfoot or ankle.
  • Neurologic diseases (Charcot Marie Tooth disease, poliomyelitis, compartment syndrome sequelae)
  • Clinical or X-ray degenerative signs (Hallux rigidus) or irreducible deformations (MTP1 arthrodesis indications).
  • Patient who declined the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
515 participants (actual)

Study arms

  • Active comparator
    No additional osteotomy

    Procedure: additional osteotomies

  • Experimental
    varisation osteotomy addition

    Procedure: additional osteotomies

  • Experimental
    supination osteotomy addition

    Procedure: additional osteotomies

  • Experimental
    both (varisation + supination) osteotomies addition.

    Procedure: additional osteotomies

Interventions

  • Procedureadditional osteotomies

    varisation osteotomy, supination osteotomy or both

06

What researchers measure

Primary outcomes

  1. Rate of patients having both Hallux Valgus Angle >15° and InterMetatarsal Angle >10°

    on weight bearing X-Rays

    Time frame: 6 months

Secondary outcomes

  1. Recurrence of hallux valgus (HVA>20°).

    Time frame: 5 years

  2. American Orthopedic Foot and Ankle Forefoot Score (AOFAS)

    Mini 0 (Worse) - Maxi 100 (Better)

    Time frame: 6 months

  3. American Orthopedic Foot and Ankle Forefoot Score (AOFAS)

    Mini 0 (Worse) - Maxi 100 (Better)

    Time frame: 5 years

  4. Patient satisfaction (Likert scale)

    very satisfied/satisfied/fairly satisfied/no satisfied

    Time frame: 6 months

  5. Patient satisfaction (Likert scale)

    very satisfied/satisfied/fairly satisfied/no satisfied

    Time frame: 5 years

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jul 2021, 22 months.

Of 51 non-industry interventional studies with no phase under Hallux Valgus, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 55. This study's 22 months is close to that.

Counting every sponsor, half of 56 studies reached it within 26 months; a quarter within 11 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2019
First posted
Oct 31, 2019
StartActual
Sep 11, 2019
Primary completionActual
Jul 29, 2021
CompletionEst.
Sep 11, 2026
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04145882
Lead sponsor
Elsan
Responsible party
Sponsor
First posted
Oct 31, 2019
Start date
Sep 11, 2019
Primary completion
Jul 29, 2021
Completion
Sep 11, 2026 (estimated)
Last update
Feb 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion